Entropy Technologies LP Acquires Shares of 39,425 Edwards Lifesciences Corporation $EW

Entropy Technologies LP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the fourth quarter, HoldingsChannel reports. The fund purchased 39,425 shares of the medical research company’s stock, valued at approximately $3,361,000.

Other institutional investors have also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $25,000. Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. Dorato Capital Management bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Finally, N.E.W. Advisory Services LLC lifted its holdings in shares of Edwards Lifesciences by 533.9% in the 4th quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 315 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of analyst reports. Barclays reaffirmed an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Finally, Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $85.02 on Monday. The firm has a market cap of $48.95 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. The firm’s 50 day simple moving average is $82.77 and its 200-day simple moving average is $83.10. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.